Using Apolipoprotein B to Manage Dyslipidemia–Reply–I.

about

Using Apolipoprotein B to Manage Dyslipidemia–Reply–I.

Item

http://www.wikidata.org/entity/Q46637657

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Using Apolipoprotein B to Manage Dyslipidemia–Reply–I.

@en

Using Apolipoprotein B to Manage Dyslipidemia–Reply–I.

@nl

type

Item

label

Using Apolipoprotein B to Manage Dyslipidemia–Reply–I.

@en

Using Apolipoprotein B to Manage Dyslipidemia–Reply–I.

@nl

prefLabel

Using Apolipoprotein B to Manage Dyslipidemia–Reply–I.

@en

Using Apolipoprotein B to Manage Dyslipidemia–Reply–I.

@nl

P1476

Using Apolipoprotein B to Manage Dyslipidemia–Reply–I.

@en

P2093

Harper CR

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association

To B or not to B: is non-high-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B?

Major lipids, apolipoproteins, and risk of vascular disease.

A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias.

ApoB versus non-HDL-C: what to do when they disagree.

The importance of non-HDL cholesterol reporting in lipid management.

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

ACP Journal Club. Either cholesterol or apolipoprotein levels can be used to determine risk for CVD; triglycerides are not useful.

Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?

Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.

P304

769-771

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4065/MCP.2010.0378

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Terry A. Jacobson

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49868399

http://www.w3.org/2001/XMLSchema#string

P921

dyslipidemias

P932

2912745

http://www.w3.org/2001/XMLSchema#string